Abstract-The effect of diethylstilboestrol (DES; 0.5 mg/100 g) and progesterone (2.5 mg/100 g) was studied on the catecholamine content of adrenals and uteri of seven day ovariectomized albino rats. The agents were administered i.p. on alternate days for one week and the tissue catecholamine content was determined spectrophoto fluorometrically.
In a previous communication from this laboratory it was reported that administration of female sex hormone to ovariectomized rats produced significant changes in the brain catecholamine levels which may be responsible for the observed central effects of these hormones on behaviour and ovulation (1) . Besides these central effects, the female sex hormones, also have some peripheral, genital and extragenital effects which are the basis for their use in the treatment of various gynaecological and emotional disorders. The deficiency of ovarian hormones, especially that of oestrogen appears to be responsible for the menopausal syndrome (2) and is characterised by hot flashes, a neurovascular phe nomenon presumed to be due to arteriolar dilatation. This syndrome can be treated ef fectively by administration of both natural and synthetic oestrogens. The mechanism by which oestrogen alleviates these symptoms remains obscure. These neurovascular effects may be due to changes in catecholamine levels in the peripheral tissues eg. adrenals which have the highest concentration of catecholamines.
Female sex hormones also modify the weight and motility of the uterus besides hav ing an effect on the cardiovascular system. There is an increased rate of uterine contrac tions during dioestrus as compared to oestrus (3). It is possible that effects of these fe male sex hormones in uterine motility may be due to alterations in the concentrations of catecholamine levels which have inhibitory effects on this organ. It was therefore thought worth-while, to estimate the levels of catecholamines in the adrenals and uteri following administration of diethyl-stilboestrol (DES) and progesterone in order to elucidate the role of catecholamines in the actions of these hormones on the cardiovascular and uterine physiology.
METHODS All experiments were conducted on adult female albino rats (K.G.M.C. Pharm. Strain) weighing between 80 and 122 g. The rats were ovariectomized one week prior to the ad ministration of sex hormones. The animals were kept on a standard diet and water was allowed ad libitum. Diethylstilboestrol (DES; 0.5 mg/100 g B.W.) or progesterone (2.5 1ng/100 g B.W.) was administered in three i.p. injections to groups of ten rats for one week on alternate days. The animals of the two treated groups and one untreated group were sacrificed by a blow on the head on the seventh day after commencement of the treatment at 11 A.M. The adrenals and uteri were immediately removed, weighed and kept in deep freeze until catecholamine estimations could be carried out.
Estimation of catecholarnines
Adrenaline, noradrenaline and dopamine were estimated spec trophotofluoro metrically by the method of Drujan et al. (4) as reported earlier by Barthwal et al. (1) .
RESULTS
The results of this study are presented in Tables 1, 2 and 3. Tables 1 and 2 show organ weights and catecholamine contents of adrenals and uteri after administration of DES and progestrone. The mean wt. of the adrenals of control group did not differ significantly from the hormone treated group of rats. On the other hand, the uteri of the animals following DES administration showed a significant increase in wt., whereas, progesterone treatment caused a decrease in the uterine wt. The results of the cate cholamine estimations show that DES treatment significantly elevated the adrenaline con tent of the adrenals, without affecting the noradrenaline content. Progesterone, on the other hand, caused a significant decrease in the adrenaline levels without altering the nor adrenaline levels (Table 1) .
In the uterus, since DES and progesterone treatment changed the total wt. of the organ, the value of catecholamines has been expressed in terms of m/ig/g, as well as m/ig/ organ. Noradrenalne and dopamine levels expressed as mpg/g were found to be sig nificantly decreased by DES treatment. This decrease in noradrenaline and dopamine content could be due to an increase in the uterine wt. rather than to a decline in the quantity of these amines. An interesting observation was a significant increase in the amount of adrenaline per uterus whereas, an insignificant change was observed in the ad renaline when expressed as mpg/g of the uterine tissue. It is, therefore, obvious that the total quantity of this amine is increased by DES treatment indicating an increase com mensurate with the increase in the uterine wt.
In contrast to DES, progesterone treatment caused a significant decrease in the con tents of adrenaline in the uterus. It also decreased the amounts of noradrenaline and dopamine per uterus but these changes were not significant statistically. Table 3 presents a summary of the statistical significance of catecholamine changes produced by DES and progesterone in adrenals and uteri. The observations that DES and progesterone produced significant changes in ad renaline content of adrenals may have some bearing on their effects on peripheral tissues. The overall picture shows that DES elevated and progesterone decreased the adrenaline levels. The administration of oestradiol 17-Q has also been reported to cause a significant increase in the quantity of adrenaline in the adrenal gland in ovariectomized rats (5) . The elevation of adrenaline content of adrenals following DES treatment may be responsible for the amelioration of hot flashes during menopause by causing an increase in the ar teriolar tone in the cutaneous vascular bed. The constriction of cutaneous vascular bed by adrenaline has been demonstrated by direct flow measurement in dogs (6) , and in hu mans (7) . Similarly, a decrease in adrenaline content of adrenals following progesterone treatment may be responsible for its hypotensive effects. Furthermore, acute fall of blood pressure occurs following adrenalectomy. The increase in adrenaline levels in adrenals by oestrogen treatment may be due to an increased conversion of noradrenaline to ad renaline. Glucocorticoids also influence the conversion of noradrenaline to adrenaline in rat adrenal gland (8) and secretion of catecholamines from rat adrenal medulla (9) . Furthermore, the effect of oestrogen on monoamine oxidase (MAO) which is an enzyme responsible for the degradation of catecholamines in the body may also assist in elevating the catecholamine levels. It has been reported that plasma MAO activity in human varies with the menstrual cycle. Plasma MAO activity was found to be less in the preovulatory phase of the cycle when the blood oestradiol level reaches peak values (10) than in the post ovulatory phase of the cycle when blood progesterone reaches peak values (11) . Further more amenorrheic women with elevated plasma MAO activity showed significant MAO suppression when treated with oral conjugated oestrogen. The addition of a progestin to the oestrogen treatment resulted in a significant rise in their plasma MAO (12) . This increase in MAO by progestin may accelerate the metabolism of catecholamines leading to a decrease in the catecholamine contents in the adrenals. Thus it appears that there is a correlation between ovarian and adrenal functions.
The functional significance of catecholamines in the uterus is unknown. There is an increased quantity of adrenaline in the uterus during oestrus as compared to dioestrus (3), whereas the quantity of noradrenaline did not vary greatly during the oestrus cycle (13) . In ovariectomized rats the quantity of adrenaline in uterus was found to be less than that observed during dioestrus. The administration of oestradiol 17-Q in ovariecto mized rats increased the quantity of adrenaline in uterus almost equal to that observed during oestrus phase (3) . This may lead to physiological changes in the motility of the uterus. It has been observed that there is an inverse relationship between uterine ad renaline level and uterine motility (3) .
We have observed that in the control group, noradrenaline, which is a transmitter in the adrenergic nervous system, is present in the highest concentration in the uterus (Table   2 ). It appears that this noradrenaline is present in the adrenergic neurons of hypogastric nerve which supplies the oviduct and uterus. The presence of dopamine in a small amount in the uterus appears to subserve a precursor role in the synthesis of noradrenaline. Ad renaline in the rat uterus was found in a small quantity of the total catecholamines present in the uterus. The small amount of adrenaline of the total catecholamines does not ap pear to play a physiological role in uterine motility. The evidence for our contentions is as follows: noradrenaline is present in the highest concentration followed by dopamine and adrenaline. Thus it appears that noradrenaline is an active transmitter in the uterus whereas dopamine is the precursor. Adrenaline present in the uterus may be due to up take from circulatory catecholamines (14, 15) . Oestrogen causes an increased force of contraction following its administration which may be due to an increase in the total mus cle mass of the uterus. The decrease in the rate of contraction after oestrogen admin istration may be due to an increase in the percentage of adrenaline in the whole tissue.
In the dioestrus phase which is due to secretion of progesterone there is a change in the adrenergic receptors. Here noradrenaline produces a contractile response rather than a relaxant effect. This action of noradrenaline which acts mainly on a-adrenore ceptors may be responsible for increased rate of uterine contractions observed during dio estrus. The fall in adrenaline level after progesterone administration may also assist in this action of noradrenaline, since adrenaline acts on both a and 8-receptors.
Thus, in conclusion it may be stated that actions of female sex hormones on cardio vascular and genital systems may be mediated through the concentration of adrenergic neurotransmitters (catecholamines) in the adrenal gland and the uterus.
